loading

LASEROPTEK

LASEROPTEK About Us
SCROLL
About Us
Company History

About Us

LASEROPTEK is an innovative force in the medical laser technology sector
We design and manufacture advanced laser systems, striving to set new standards in aesthetic and medical treatments worldwide.

Our mission is to become a global leader in laser technology through continuous innovation and unwavering commitment to quality.
With each product we develop, we move closer to realizing this vision.

Our Vision

Company History

Establishment Years 2000 ~ 2010

  • Found~
    While working as a senior researcher at the Korea
    Institute of Science and Technology (KIST)
    Founded LASEROPTEK as a venture startup
  • 2000
    Establishment of LASEROPTEK Co., Ltd.
    and Research Center, commencing development of
    semiconductor lasers (Completion of 1-year
    project for national task)
    Supply of industrial lasers to Taiwan's TSMC,
    KYEC, APE, ASE, and Japan's Sharp, Toyota
  • 2003
    Domestic launch of the domestically
    developed Er:YAG laser LOTUS
    Domestic launch of the domestically
    developed Q-switched Nd:YAG laser HELIOS
  • 2007
    Release of LOTUSII
  • 2009
    HELIOSII and LOTUSII receive U.S.
    FDA 510(k) and European CE approval
로고 이미지
텍스트 이미지 - raser

Development Years 2011 ~ 2017

  • 2011
    Awarded $3 million Export Tower
  • 2012
    Domestic release of Nd:YAG
    Long Pulse Laser - HYPERION
  • 2013
    Domestic release of HELIOSIII
  • 2014
    Domestic release of Alexandrite,
    Long Pulse Laser, ZELOS
  • 2015
    World's first solid-state UVB laser
    PALLAS released, LOTUS III domestic release
  • 2016
    Domestic release of HELIOS III
    and FDA 510(k) and CE approval
  • 2017
    PALLAS receives FDA 510(k)
    and CE approval
연구원
텍스트 이미지 - optek

Growth Years 2018 ~ Current

  • 2018
    Appointment of CEO Lee Chang-jin,
    Domestic release of PicoLO Picosecond Laser
    LOTUS III FDA 510(k) approval
    First domestic laser company to receive
    MDSAP certification
  • 2019
    FDA 510(k) approval for PicoLO
    Domestic release of PicoLO PREMIUM
    Winner of the Korean Technology Award
    Awarded $5 million Export Tower
  • 2020
    Global Strong Company Designation
    for PicoLO and LOTUS III
    CE approval for PicoLO and PALLAS
    Selected as an 'Industrial Innovation
    Company' by the Industrial Bank of Korea
    Winner of the 'Minister of Trade,
    Industry and Energy Award' at the Monthly
    Industrial Technology Awards
    Attracted ₩10 billion investment
    from Woori Investment Partners
  • 2021
    CE approval for PicoLO PREMIUM
    and HELIOS 785
    Domestic release of HELIOS 785
    PicoLO and PicoLO PREMIUM selected
    as Next-Generation World-Class Products
  • 2022
    Domestic release of PALLAS PREMIUM
    FDA 510(k) approval for HELIOS 785
    Awarded $10 million Export Tower
    Commendation from the Minister of
    SMEs and Startups as an Export Pioneer
    Commendation from the Gyeonggi-do
    Province for Contributions to the
    Advancement of Science and Technology
  • 2023
    Awarded for Contributions to the
    Advancement of Science and Technology
    by Gyeonggi-do Province
    Commendation from the Korea Medical
    Device Industry Association by
    the Commissioner of the Korea Food
    and Drug Administration and the
    Director of the Health Insurance
    Review & Assessment Service
    PALLAS PREMIUM FDA 510(k) approval
    PALLAS PREMIUM and HELIOS 785 receive
    PICO approval in Taiwan"
도심